
|Videos|March 19, 2015
The Role of High-Dose IL-2 in RCC
Author(s)Mario Sznol, MD
Mario Sznol, MD, professor of medicine, Yale Cancer Center, discusses the role of high-dose IL-2 for the treatment of renal cell carcinoma (RCC).
Advertisement
Clinical Pearls
Mario Sznol, MD, professor of medicine, Yale Cancer Center, discusses the role of high-dose IL-2 for the treatment of renal cell carcinoma (RCC).
- There is still a role for high-dose IL-2 in RCC.
- Anti-PD-1 agents are active, but a different population of patients may respond to high-dose IL-2.
- Both agents are necessary to achieve durable remissions.
- If combinations with anti-PD-1 agents prove to be active, IL-2 may be moved to the second- or third-line.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
FDA Oncology Update January 2026: New Horizons in Precision Medicine
5



















